CD69 and neoplasm: Notably, CD69 expression, an activation marker for CD8+ T lymphocytes, significantly increased in the combination treatment group in contrast to the PBS group, PLX3397 group, and RT group within the Lewis subcutaneous transplant tumor model (Fig. 2F).